Somatic mutation

Stanford to use Sequentify kits for Hematological Malignancies NGS Sequencing

Retrieved on: 
Wednesday, November 8, 2023
Regenerative medicine, Acute myeloid leukemia, DNA sequencing, Entrepreneurship, Research, Genomics, NGS, Somatic mutation, Virology, AI, Synthetic biology, National Democratic Front of the Philippines, Automation, AML, Weizmann Institute of Science, DNA, Stanford University School of Medicine, Fine chemical

Founded in 2021, Sequentify democratizes genomics by providing DNA library preparation for Next Generation Sequencing (NGS) and AI software that enables fast, cost-effective and automated sequencing.

Key Points: 
  • Founded in 2021, Sequentify democratizes genomics by providing DNA library preparation for Next Generation Sequencing (NGS) and AI software that enables fast, cost-effective and automated sequencing.
  • Sequentify's NGS products are based on its InfiniSeq proprietary platform and include cancer diagnostics, carrier screening, virology and other applications.
  • Tom Fleischer, Co-Founder and CEO of Sequentify added: "We are excited to work with Stanford Medicine, a world leading research institute and hospital, on implementing cost effective and high throughput NGS sequencing for myeloid conditions."
  • The patent-pending InfiniSeq technology is adjustable to most sequencing machines and fits into any lab workflow.

Turnstone Biologics Presents Preclinical Data Highlighting Potential for Selected Tumor-Infiltrating Lymphocyte (TIL) Therapy in Solid Tumors at the 2023 Society for Immunotherapy of Cancer (SITC) Annual Meeting

Retrieved on: 
Friday, November 3, 2023
Neoplasm, Colon, Breast, Stomach, Somatic mutation, RNA, Society for Immunotherapy of Cancer, CRISPR, TIL, SITC, Immunotherapy, Selection, Annual general meeting, Gene, Melanoma, Society, Liquid biopsy, Patient, SAN, DNA, Pharmaceutical industry, Medical imaging, Turnstone

SAN DIEGO, Nov. 03, 2023 (GLOBE NEWSWIRE) -- Turnstone Biologics Corp. (“Turnstone” or the “Company”) (Nasdaq: TSBX), a clinical-stage biotechnology company developing a differentiated approach to treat and cure patients with solid tumors by pioneering selected tumor-infiltrating lymphocyte (Selected TIL) therapy, today announced it will be presenting four posters highlighting preclinical data from its pipeline of programs, including the lead clinical candidate, TIDAL-01, at the Society for Immunotherapy of Cancer (SITC) 38th Annual Meeting being held November 1-5, 2023 in San Diego, California.

Key Points: 
  • We are pleased to share the promising results presented at SITC that further highlight our differentiated approach.
  • Identifying tumor-specific neoantigens arising from somatic mutations is one of the differentiating features of Turnstone’s Selected TIL process for TIDAL-01.
  • Distinct from, yet complementary to TIDAL-01, Turnstone is developing a preclinical program associated with a next-generation direct selection process.
  • Turnstone scientists are presenting preclinical data highlighting that directly selected tumor-reactive TIL can be genetically engineered using CRISPR-Cas and demonstrate that knocking out genes of interest can potentially enhance directly selected TIL quality and function.

Somatic Mutations in Single-Cell Sequencing: Separating Signal from Noise, Upcoming Webinar Hosted by Xtalks

Retrieved on: 
Monday, October 16, 2023
Health informatics, Somatic mutation, Cell, Algorithm, DNA, Whole genome sequencing, SNV calling from NGS data, Doctor of Philosophy, PTA, DNA repair, Harvard Medical School, Cell division, Postdoctoral researcher, Antibiotics, Vaccine

TORONTO, Oct. 16, 2023 /PRNewswire-PRWeb/ -- Discover a groundbreaking webinar delving into the development of SCAN2 and how this algorithm enables single-cell sequencing with high accuracy for somatic mutations. Somatic mutations arise due to DNA damage or errors in DNA synthesis and are propagated through cell division. Unlike inherited variants, somatic mutations are shared by only a fraction of the cells in an organism. Numerous algorithms have been developed to identify somatic mutations present in clonal populations in cancer cells. But, for non-cancer cells, the majority of somatic mutations — other than those that arise very early in development — are shared by very few cells or can even be private to a single cell. To identify such mutations, new detection techniques are required.

Key Points: 
  • In this free webinar, delve into the development of SCAN2 and how this algorithm enables single-cell sequencing with high accuracy for somatic mutations.
  • TORONTO, Oct. 16, 2023 /PRNewswire-PRWeb/ -- Discover a groundbreaking webinar delving into the development of SCAN2 and how this algorithm enables single-cell sequencing with high accuracy for somatic mutations.
  • Somatic mutations arise due to DNA damage or errors in DNA synthesis and are propagated through cell division.
  • Join this webinar to gain insights into the SCAN2 algorithm and how it enables single-cell sequencing with high accuracy for somatic mutations.

Xtalks Announces its Life Science Webinar Calendar for October 2023

Retrieved on: 
Monday, October 2, 2023
Sample, REMS, Gene, Health, Alzheimer's disease, Drug discovery, Somatic mutation, Personalized medicine, Evolution, Biomedical Research, Biomarker, MADRS, Marketing, Unexpected, Future, Retinal gene therapy using lentiviral vectors, Clinical trial, Biomedicine, Analysis, Lost, Clinical research, Weight loss, Management, Patient, Approved Drug Products with Therapeutic Equivalence Evaluations, SENSOR-Pesticides, DSM-IV codes, Pharmacology, Noise, Update, Pharmaceutical industry, Medical imaging, Vaccine, Cryptocurrency, Medical device, Xtalk

TORONTO, Oct. 2, 2023 /PRNewswire-PRWeb/ -- Stay on top of current hot topics through free webinars presented by leading experts in the pharma, biotech, medical device and food industries. Access to all webinars is free, so be sure to register today to save your place! Participate in the discussion and stay relevant in your field!

Key Points: 
  • Upcoming free, educational webinars from Xtalks will feature topics on biomarkers, cell and gene therapy, clinical trials, commercialization & HEOR, drug discovery & development, fundamental research, healthcare, laboratory technology, medical device, patient recruitment & retention, pharma manufacturing & supply chain, pharmaceutical regulation and preclinical.
  • TORONTO, Oct. 2, 2023 /PRNewswire-PRWeb/ -- Stay on top of current hot topics through free webinars presented by leading experts in the pharma, biotech, medical device and food industries.
  • Access to all webinars is free, so be sure to register today to save your place!
  • Participate in the discussion and stay relevant in your field!

Whole Genome Amplification: Studying Tissue Mosaicism and Evolution with Primary Template-Directed Amplification, Upcoming Webinar Hosted by Xtalks

Retrieved on: 
Wednesday, August 2, 2023
Somatic mutation, PTA, Genetic variation, Associate, Genomics, Idiopathic osteosclerosis, Life, Cell, Stanford University, Genome, Antibiotics, Vaccine

TORONTO, Aug. 2, 2023 /PRNewswire-PRWeb/ -- Explore the cutting edge of genomic research in an upcoming webinar, focusing on whole genome amplification and its role in understanding tissue mosaicism and evolution.

Key Points: 
  • TORONTO, Aug. 2, 2023 /PRNewswire-PRWeb/ -- Explore the cutting edge of genomic research in an upcoming webinar, focusing on whole genome amplification and its role in understanding tissue mosaicism and evolution.
  • Dr. Charles Gawad, an Associate Professor at Stanford University and co-Founder of BioSkryb Genomics , will serve as the primary speaker.
  • The live webinar , titled "Whole Genome Amplification: Studying Tissue Mosaicism and Evolution with Primary Template-Directed Amplification," will take place on Tuesday, August 22, 2023, at 2pm EDT (8pm CEST/EU-Central).
  • BioSkryb has partnered with Xtalks to bring this insightful webinar to a broad audience of researchers, academics and industry professionals.

Enterome announces first patient dosed in Phase 2 trial with OncoMimics™ immunotherapy EO2040 in Colorectal Cancer with ctDNA-defined Minimal Residual Disease

Retrieved on: 
Tuesday, July 11, 2023
Molecular mimicry, DNA, Circulating tumor DNA, BIRC5, CRC, Liquid biopsy, Cancer, Immunotherapy, Rated R, Trial of the century, MD Anderson Cancer Center, MRD, Service provider, CD8, FOXM1, Patient, Risk, Colorectal cancer, University, Blood, Somatic mutation, Epitope, Neoplasm, UCP2, DFS, Nivolumab, Pharmaceutical industry, Vaccine, Medical imaging

EO2040 is an innovative, off-the-shelf immunotherapy that combines two synthetic OncoMimics™ peptides.

Key Points: 
  • EO2040 is an innovative, off-the-shelf immunotherapy that combines two synthetic OncoMimics™ peptides.
  • These non-self, microbial-derived peptides correspond to CD8 HLA-A2 epitopes that exhibit molecular mimicry with the tumor-associated antigens (TAAs) FOXM1 & BIRC5.
  • EO2040 also includes universal cancer peptide 2 (UCP2), a helper peptide representing the CD4+ epitope.
  • The CLAUDE study (EOCRC1-22; NCT05350501) is the first trial to use liquid biopsy monitoring to measure ctDNA clearance as an indicator of OncoMimics™ immunotherapy efficacy.

Genomic Urine Test Detects Bladder Cancer from DNA Up to 12 Years Before Clinical Signs and Symptoms Appear

Retrieved on: 
Monday, May 1, 2023
Carcinoma, DNA, University, University of Texas Southwestern Medical Center, Urine, SBIR, Genomics, Neoplasm, AUA, University of Texas at Austin, Convergent, Cancer, American Urological Association, Quality of life, Risk assessment, Bladder cancer, Prognosis, American Cancer Society, Doctor of Philosophy, Assistant, Harvard Medical School, National Cancer Institute, MD, Patient, Small Business Innovation Research, Risk, Machine learning, Chemoprophylaxis, Annual general meeting, Cystoscopy, Somatic mutation, Diagnosis, Massachusetts General Hospital, Recurrence, Gene, Genome, Disease, Medical imaging, Vaccine, Pharmaceutical industry, Urology

CHICAGO, May 1, 2023 /PRNewswire/ -- A new genomic urine test can help doctors accurately predict bladder cancer as many as 12 years before clinical signs and symptoms emerge and long before a diagnosis can be made with cystoscopy, the most common method of detection, according to a new study* presented here at the 2023 American Urological Association (AUA) Annual Meeting.

Key Points: 
  • Developed by Convergent Genomics , the UroAmp test uses next-generation DNA sequencing and machine learning to analyze urine for mutations across 60 genes linked to bladder cancer while also measuring the entire genome.
  • "With further studies, this discovery could improve how we identify, risk stratify and monitor patients at increased risk of developing bladder cancer."
  • First, they conducted a case-control study with urine samples from 96 control subjects and 70 bladder cancer patients (22 de novo, 48 surveillance).
  • Specificity, or the percentage of people who tested negative for bladder cancer and do not have the disease, was 94%.

Lupus Research Alliance Grants 2023 Lupus Innovation Awards to Advance Ground-Breaking Lupus Research

Retrieved on: 
Thursday, March 23, 2023
Infection, Drug development, Lupus Research Alliance, APS, LRA, Prusa i3, Quality of life, LIA, Research, Brain, Lupus, Biomarker, Kidney, Antibody, Proteinuria, Death, MRI, Protein, Magnetic resonance imaging, Patient, Blood, Immune system, VISTA, Lupus nephritis, Somatic mutation, Discoid lupus erythematosus, Thrombosis, Photosensitivity, Glycosylation, Gene, Skin, Award, Disease, Pharmaceutical industry, Medical imaging, Vaccine, Medical device, Doctor of Philosophy, Health

NEW YORK, March 23, 2023 /PRNewswire/ --The Lupus Research Alliance (LRA) today announced the recipients of the newest Lupus Innovation Award (LIA) grants.

Key Points: 
  • NEW YORK, March 23, 2023 /PRNewswire/ --The Lupus Research Alliance (LRA) today announced the recipients of the newest Lupus Innovation Award (LIA) grants.
  • "We are proud to be able to offer these grants, which support critical lupus research and encourage the development of novel therapeutic approaches.
  • The LRA LIA grants provide support for pioneering, high-risk, high-reward approaches to significant challenges in lupus research.
  • This research will increase the understanding of how lupus impacts the brain and help identify new potential treatment targets for neuropsychiatric lupus.

Hadassah Cancer Research Institute (HCRI) Unveils a Breakthrough in Personalized Cancer Care with a Data-Driven, Gene Targeting Tool

Retrieved on: 
Monday, February 27, 2023
Cancer, MD, Disease, Gene, Risk, Research, Prognosis, Patient, Somatic mutation, HCRI, Radiation therapy, Computational biology, Laboratory, Gene targeting, Medical imaging

JERUSALEM, Feb. 27, 2023 /PRNewswire/ -- The Hadassah Cancer Research Institute at the Hadassah University Medical Center in Jerusalem, announced today that researchers have designed a genomic analysis tool for cancer patients that enables advanced selection of drugs targeting schemes for cancer genes, opening the door to improved personalized medicine in cancer treatment. The science behind this breakthrough tool is a computational biology method to assess the relative effect of each position-specific point mutation in 535 cancer genes, by quantifying the relative biological and clinical importance of point mutations. This enables the prioritization of genes for targeting and will lead to the development of new, more effective combination therapies, further improving the prognosis for cancer patients.

Key Points: 
  • JERUSALEM, Feb. 27, 2023 /PRNewswire/ -- The Hadassah Cancer Research Institute at the Hadassah University Medical Center in Jerusalem, announced today that researchers have designed a genomic analysis tool for cancer patients that enables advanced selection of drugs targeting schemes for cancer genes, opening the door to improved personalized medicine in cancer treatment.
  • This enables the prioritization of genes for targeting and will lead to the development of new, more effective combination therapies, further improving the prognosis for cancer patients.
  • "With this new gene targeting tool, we are finally able to bring the power of personalized medicine to the forefront of cancer care.
  • For more information on the Hadassah Cancer Research Institute, contact:

China Biotech Services subsidiary AMDL nominated as Top Clinical Laboratory Services Company in APAC 2022 and receives CAP Accreditation Certificate

Retrieved on: 
Tuesday, January 10, 2023
Pillar, NGS, Certification, Lung, DNA, FDA, CAP, College, Accreditation, HK, Oncology, Workflow, Somatic mutation, Cdx

HK) has announced that its subsidiary, Asia Molecular Diagnostics Laboratory (AMDL), has been nominated as the Top Clinical Laboratory Services Company in APAC 2022 and has received the College of American Pathologists (CAP) Accreditation Certificate for providing next-generation sequencing (NGS) Oncology clinical testing services.

Key Points: 
  • HK) has announced that its subsidiary, Asia Molecular Diagnostics Laboratory (AMDL), has been nominated as the Top Clinical Laboratory Services Company in APAC 2022 and has received the College of American Pathologists (CAP) Accreditation Certificate for providing next-generation sequencing (NGS) Oncology clinical testing services.
  • With world-leading NGS-based clinical testing products and services for oncologists and a high-standard molecular-level clinical laboratory, and as the sole distributor of Pillar Biosciences products in Asia, it's no surprise that AMDL has been named one of the industry's Top Clinical Laboratory Services Companies in APAC 2022 by Life Sciences Review.
  • In addition, AMDL has recently received the Accreditation Certificate from CAP, which is recognized as one of the industry's leaders in medical laboratory quality assurance.
  • It has developed detailed checklists for all aspects of clinical laboratory disciplines and has strict requirements for laboratory quality standards.